Overview |
bs-0115R-FITC |
AKT1/2/3 Polyclonal Antibody, FITC Conjugated |
WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat, Bovine, Pig, Others |
Dog, Cow, Sheep, Chicken |
Specifications |
FITC |
Rabbit |
KLH conjugated synthetic peptide derived from human AKT1 |
401-479/479 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
207 |
P31749 |
Cytoplasm, Nucleus, Cell membrane |
AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA; RAC-alpha serine/threonine-protein kinase; Protein kinase B; Protein kinase B alpha; PKB alpha; Proto-oncogene c-Akt; RAC-PK-alpha; AKT1; RAC-gamma serine/threonine-protein kinase; Protein kinase Akt-3; Protein kinase B gamma; PKB gamma; RAC-PK-gamma; STK-2; PKBG |
AKT1-specific substrates have been recently identified, including palladin (PALLD), which phosphorylation modulates cytoskeletal organization and cell motility; prohibitin (PHB), playing an important role in cell metabolism and proliferation; and CDKN1A, for which phosphorylation at 'Thr-145' induces its release from CDK2 and cytoplasmic relocalization. These recent findings indicate that the AKT1 isoform has a more specific role in cell motility and proliferation. Phosphorylates CLK2 thereby controlling cell survival to ionizing radiation. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |